Volker Herrmann, M.D.

Volker Herrmann is CEO of Sonata Therapeutics and a Flagship Pioneering CEO-Partner. Volker was previously the CEO of Inzen Therapeutics, a predecessor to Sonata, and COO and President at SQZ Biotechnologies. Prior to SQZ, he held various leadership roles of increasing responsibility at Pfizer. He also served as CCO of Viamet Pharmaceuticals and COO of Selenity Therapeutics. Volker received his M.D. from Albert-Ludwigs University Freiburg in Germany and an MBA from the University of San Diego.